Navigation Links
Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
Date:4/18/2013

NEW BRUNSWICK, N.J., April 18, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the sale to Elan Corporation, plc of approximately 82 million American Depositary Shares (ADS) of Elan held by Janssen Pharmaceutical (Janssen), an affiliate of Johnson & Johnson.  This sale took place in accordance with the "Dutch Auction" tender offer commenced by Elan on March 11, 2013.  The aggregate proceeds are expected to be received on or before April 30, 2013.

Janssen will receive $11.25 per ADS which will result in an after-tax gain of approximately $213 million and will be recorded by Johnson & Johnson in the second quarter. The Company expects to invest this gain in the business. It is not expected to impact earnings per share guidance for full-year 2013 which was previously announced on April 16, 2013.

About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceutical and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson Electric Launches Medication Dosing Systems
2. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
3. Johnson & Johnson gibt Eröffnung des Innovationszentrums in London bekannt
4. Johnson & Johnson Announces Opening of London Innovation Centre
5. Kevin Johnson Joins United Allergy Services Board Of Directors
6. Free Research Report on Delta Air Lines, Inc., Johnson & Johnson, Barrick Gold Corp., Exelon Corp. and Cirrus Logic, Inc.
7. Huntington Memorial Hospital Elects Paul Johnson, Deborah Williams to its Board of Directors
8. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
9. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
10. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
11. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... ... and Richard Pedranti Architect (RPA), a full-service architecture firm focusing on ... Solsken Line of Model Homes . Independently, Ecocor and RPA have extensive ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... consulting firm in Pennsylvania, is pleased to offer in-home and online newborn ... that sleep deprivation has on the body,” says company owner Courtney Zentz, a ...
(Date:9/22/2017)... ... , ... Happy Living’s mission - to improve the health and wellbeing of ... and delicious worlds of theatre and wines. , After watching Scott Barry perform ... his play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was published ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed ... of an obligatory tithe, and the freedom experienced when breaking free from this ... published author, Lysa M. Harrison. , Published by Christian Faith Publishing, Lysa M. ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice Emergency ... the one year anniversary of its Houston-Fallbrook facility. , “We are honored ... Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a pleasure ...
Breaking Medicine News(10 mins):